Evidence map›Paper›PMID 27111806›Full record

ArticleJAMA internal medicine2016

Effect of Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence of C difficile Infections: A Quasi-Experimental Controlled Study.

Yves Longtin, Bianka Paquet-Bolduc, Rodica Gilca, Christophe Garenc, Elise Fortin, Jean Longtin, Sylvie Trottier, Philippe Gervais, Jean-François Roussy, Simon Lévesque and 3 more

Registry-linked trialAbstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in JAMA internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03223415 (Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections; A Cluster Randomized Feasibility Trial), which is not on this map. Cited by 97 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 2 pooled it
25.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03223415 nacompletednot on this mapstarted 2017, after this paper: background citation

Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections; A Cluster Randomized Feasibility Trial

TypeinterventionalSponsorYves LongtinRan2017 to 2018Enrolled4,138ConditionsClostridium DifficileArmsDetection and isolation of C. difficile carriers
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 210 citations in OpenAlex.

  1. The value of fecal calprotectin inFrontiers in physiology · 2022
    Pooled it
  2. Guideline
  3. Optimized Surveillance Testing for ToxigenicmedRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Investigating in-hospital transmission ofJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
    Article
  9. The Global Burden ofInfectious disease reports · 2025
    Review
  10. Review
  11. Predicting positiveHeliyon · 2025
    Article
  12. Article
  13. Article
  14. Core genome multilocus sequence typing of Clostridioides difficile to investigate transmission in the hospital setting.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  15. Estimating the effect of active detection and isolation onInfection control and hospital epidemiology · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Strategies to preventInfection control and hospital epidemiology · 2023
    Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Yves LongtinInfection Prevention and Control Unit, Jewish General Hospital Sir Mortimer B. Davis, Montreal, Québec, Canada2Faculty of Medicine, McGill University, Montreal, Québec, Canada.
Bianka Paquet-BolducInfection Control Unit, Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec City, Canada.
Rodica GilcaInstitut National de Santé Publique du Québec, Québec City, Canada5Centre Hospitalier Universitaire de Québec, Québec City, Canada6Faculty of Medicine, Université Laval, Québec City, Québec, Canada.
Christophe GarencInstitut National de Santé Publique du Québec, Québec City, Canada7Centre de Recherche en Infectiologie de l'Université Laval, Québec City, Québec, Canada.
Elise FortinInstitut National de Santé Publique du Québec, Québec City, Canada.
Jean LongtinCentre Hospitalier Universitaire de Québec, Québec City, Canada6Faculty of Medicine, Université Laval, Québec City, Québec, Canada7Centre de Recherche en Infectiologie de l'Université Laval, Québec City, Québec, Canada8Laboratoire de Santé Publique du Qué
Sylvie TrottierCentre Hospitalier Universitaire de Québec, Québec City, Canada6Faculty of Medicine, Université Laval, Québec City, Québec, Canada7Centre de Recherche en Infectiologie de l'Université Laval, Québec City, Québec, Canada9Department of Infectious Diseases, I.
Philippe GervaisCentre Hospitalier Universitaire de Québec, Québec City, Canada6Faculty of Medicine, Université Laval, Québec City, Québec, Canada9Department of Infectious Diseases, Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec City, Canada.
Jean-François RoussyCentre Hospitalier Universitaire de Québec, Québec City, Canada6Faculty of Medicine, Université Laval, Québec City, Québec, Canada9Department of Infectious Diseases, Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec City, Canada.
Simon LévesqueLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada.
Debby Ben-DavidInfectious Diseases Unit, Chaim Sheba Medical Center, Tel HaShomer, Israel.
Isabelle CloutierDepartment of Pharmacy, Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec City, Canada.
Vivian G LooFaculty of Medicine, McGill University, Montreal, Québec, Canada12Division of Infectious Diseases, McGill University Health Centre, Montreal, Québec, Canada.
Centre hospitalier universitaire de Québec · CAInstitut National de Santé Publique du Québec · CAInstitut Universitaire de Cardiologie et de Pneumologie de Québec · CAMcGill University · CAMcGill University Health Centre · CASheba Medical Center · ILUniversité Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceClostridium difficile infection (CDI) is a major cause of health care-associated infection worldwide, and new preventive strategies are urgently needed. Current control measures do not target asymptomatic carriers, despite evidence that they can contaminate the hospital environment and health care workers' hands and potentially transmit C difficile to other patients.

objectiveTo investigate the effect of detecting and isolating C difficile asymptomatic carriers at hospital admission on the incidence of health care-associated CDI (HA-CDI). DESIGN, SETTING, AND

participantsWe performed a controlled quasi-experimental study between November 19, 2013, and March 7, 2015, in a Canadian acute care facility. Admission screening was conducted by detecting the tcdB gene by polymerase chain reaction on a rectal swab. Carriers were placed under contact isolation precautions during their hospitalization. MAIN OUTCOMES AND MEASURES: Changes in HA-CDI incidence level and trend during the intervention period (17 periods of 4 weeks each) were compared with the preintervention control period (120 periods of 4 weeks each) by segmented regression analysis and autoregressive integrated moving average (ARIMA) modeling. Concomitant changes in the aggregated HA-CDI incidence at other institutions in Québec City, Québec (n = 6) and the province of Québec (n = 94) were also examined.

resultsOverall, 7599 of 8218 (92.5%) eligible patients were screened, among whom 368 (4.8%) were identified as C difficile carriers. During the intervention, 38 patients (3.0 per 10 000 patient-days) developed an HA-CDI compared with 416 patients (6.9 per 10 000 patient-days) during the preintervention control period (P < .001). There was no immediate change in the level of HA-CDIs on implementation (P = .92), but there was a significant decrease in trend over time of 7% per 4-week period (rate ratio, 0.93; 95% CI, 0.87-0.99 per period; P = .02). ARIMA modeling also detected a significant effect of the intervention, represented by a gradual progressive decrease in the HA-CDI time series by an overall magnitude of 7.2 HA-CDIs per 10 000 patient-days. We estimated that the intervention had prevented 63 of the 101 (62.4%) expected cases. By contrast, no significant decrease in HA-CDI rates occurred in the control groups. CONCLUSIONS AND RELEVANCE: Detecting and isolating C difficile carriers was associated with a significant decrease in the incidence of HA-CDI. If confirmed in subsequent studies, this strategy could help prevent HA-CDI.

Indexed as

Patient AdmissionCanadaCarrier StateClostridioides difficileClostridium InfectionsCross InfectionDisease OutbreaksEmergency Service, HospitalEnterocolitis, PseudomembranousHospitals, UniversityHumansIncidenceQuebecRectumRetrospective Studies

Identifiers

PMID27111806
OpenAlexW2343435145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.